Iterum Therapeutics PLC

NASDAQ ITRM

Data sourced from iex and EODHD
Download Data

Iterum Therapeutics PLC Net Income for the quarter ending March 31, 2024: USD -7.10 M

Iterum Therapeutics PLC Net Income is USD -7.10 M for the quarter ending March 31, 2024, a 28.19% change year over year. Net Income is the profit earned by a company after deducting all expenses, including taxes and non-controlling interest.
  • Iterum Therapeutics PLC Net Income for the quarter ending March 31, 2023 was USD -9.89 M, a -182.54% change year over year.
  • Iterum Therapeutics PLC Net Income for the quarter ending March 31, 2022 was USD -3.50 M, a 96.46% change year over year.
  • Iterum Therapeutics PLC Net Income for the quarter ending March 31, 2021 was USD -98.92 M, a -514.42% change year over year.
  • Iterum Therapeutics PLC Net Income for the quarter ending March 31, 2020 was USD -16.10 M, a 21.77% change year over year.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

USD 1.17

0.00%

StockViz Staff

September 8, 2024

Any question? Send us an email